• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors

    3/26/24 8:00:00 AM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $OBIO alert in real time by email
    • David Pacitti is currently the President of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers; formerly Division Vice President of U.S. Commercial Operations, Sales, and Marketing at Abbott Vascular

    • Mr. Pacitti brings nearly 30 years of experience in cardiovascular device and procedural imaging experience to the Orchestra BioMed Board of Directors after previously serving as a strategic advisor during the formation of the company

    NEW HOPE, Pa., March 26, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of David Pacitti to its Board of Directors, effective as of March 26, 2024. Mr. Pacitti is currently the President of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers. Prior to joining Siemens Healthineers, he was Division Vice President of U.S. Commercial Operations, Sales, and Marketing at Abbott Vascular, overseeing the company's business in North America. As a member of the Senior Executive Staff, he worked with the CEO, CFO, and Research & Development team on business development initiatives and played pivotal roles in key launches, including Abbott Vascular's first drug-eluting stent and structural heart franchise.

    "It's an honor to welcome Dave to the Orchestra BioMed Board where we expect to benefit from his wealth of experience in driving the adoption of transformational device therapies and procedural imaging modalities," said David Hochman, chairman, chief executive officer and founder of Orchestra BioMed. "Dave is a big thinker who believes in the power of partnerships and novel, out-of-the-box strategic collaboration to bring new technologies to patients, improve healthcare delivery and drive better outcomes. His extensive experience and broad network in interventional cardiology and cardiac rhythm management will add further strength to our knowledge and connections in those large, established markets that are core to our current pipeline. Having previously served as a strategic advisor, Dave is familiar with our strategy, differentiated business model and pipeline. We believe he can help guide the work we are doing with our existing programs and partnerships while also helping us identify and execute on new opportunities to leverage our partnership-enabled business model."

    Mr. Pacitti commented, "I am thrilled to join the Orchestra BioMed Board and continue working with what I know to be an exceptional leadership team. AVIM therapy and Virtue SAB represent the kind of high-impact, transformational device-based therapies that I have helped commercialize my entire career. Moreover, I believe the Company's novel, partnership driven business model, exemplified by the strategic collaborations in place with Medtronic and Terumo, is timely and necessary in an increasingly difficult environment for medical device innovation. I look forward to contributing my perspective to help Orchestra BioMed realize the full potential of its cardiovascular pipeline, strategic partnerships and differentiated business model."

    About Orchestra BioMed

    Orchestra BioMed (NASDAQ:OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed's partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed's lead product candidate is atrioventricular interval modulation (AVIM) therapy (also known as BackBeat Cardiac Neuromodulation Therapy (CNT™)) for the treatment of hypertension, a significant risk factor for death worldwide. Orchestra BioMed is also developing Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed has additional product candidates and plans to potentially expand its product pipeline through acquisitions, strategic collaborations, licensing and organic development. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.

    References to Websites and Social Media Platforms

    References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

    Forward-Looking Statements

    Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the potential efficacy and safety of the Company's commercial product candidates, the ability of the Company's partnerships to accelerate clinical development, and the Company's late-stage development programs, strategic partnerships and plans to expand its product pipeline. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to regulatory approval of the Company's product candidates and ongoing regulation of the Company's product candidates, if approved; the timing of, and the Company's ability to achieve, expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading "Item 1A. Risk Factors" in the Company's quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 12, 2023, as updated by any risk factors disclosed under the heading "Item 1A. Risk Factors" in the Company's subsequently filed quarterly reports on Form 10-Q, as well as the risk factors that will be included in the Company's annual report on Form 10-K for the year ended December 31, 2023, which is expected to be filed with the SEC on March 27, 2024.

    The Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, the Company cautions against placing undue reliance on these forward-looking statements, which only speak as of the date of this press release. The Company does not plan and undertakes no obligation to update any of the forward-looking statements made herein, except as required by law.

    Investor Contact:

    Bob Yedid

    LifeSci Advisors

    (516) 428-8577

    [email protected]

    Media Contact:

    Kelsey Kirk-Ellis

    Orchestra BioMed

    (484) 682-4892

    [email protected]



    Primary Logo

    Get the next $OBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OBIO

    DatePrice TargetRatingAnalyst
    3/20/2025$12.00Buy
    BTIG Research
    1/2/2025$16.00Overweight
    Barclays
    8/22/2024$14.00Buy
    H.C. Wainwright
    7/25/2024$15.00Buy
    B. Riley Securities
    1/19/2024$14.00Buy
    Jefferies
    2/24/2023$15.00Overweight
    Piper Sandler
    2/7/2023$20.00Buy
    Chardan Capital Markets
    More analyst ratings

    $OBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Orchestra BioMed with a new price target

      BTIG Research initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $12.00

      3/20/25 8:00:48 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Barclays initiated coverage on Orchestra BioMed with a new price target

      Barclays initiated coverage of Orchestra BioMed with a rating of Overweight and set a new price target of $16.00

      1/2/25 8:04:57 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • H.C. Wainwright initiated coverage on Orchestra BioMed with a new price target

      H.C. Wainwright initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $14.00

      8/22/24 7:33:07 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care

    $OBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Rtw Investments, Lp bought $149,201 worth of shares (49,900 units at $2.99) (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      5/1/25 8:18:11 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Rtw Investments, Lp bought $126,500 worth of shares (50,000 units at $2.53) (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      4/29/25 5:16:34 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Officer Hochman David P was granted 98,333 shares, increasing direct ownership by 20% to 579,498 units (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      4/4/25 9:44:39 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care

    $OBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

      Secured ten new fully-issued patents related to hypertension treatment during last 12 months, bringing global issued patent estate total for this condition to 120 patentsPatent estate covering atrioventricular interval modulation ("AVIM") therapy now includes 46 issued U.S. patents and 91 patents outside the U.S. that collectively comprise over 2100 claims related to the treatment of hypertension as well as heart failureHeart failure pipeline program now protected by an additional 17 issued global patents FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular risk, including those at risk of heart fa

      5/7/25 8:30:00 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

      Orchestra BioMed's Virtue® Sirolimus AngioInfusion Balloon™ ("Virtue SAB") is the only non-coated drug-eluting balloon system under clinical investigation worldwide and has been awarded multiple FDA Breakthrough Device DesignationsThe Virtue Trial will be the first U.S. IDE head-to-head randomized evaluation of a sirolimus-eluting balloon versus a commercially available paclitaxel-coated balloon (AGENT™) for the treatment of coronary in-stent restenosis ("ISR")Robust non-inferiority trial is designed to provide a clear pathway to regulatory approval as well as potentially showcase clinical advantages of Virtue SABWith the amended IDE approved by the FDA, Orchestra BioMed is currently targeti

      4/29/25 9:00:00 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

      NEW HOPE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will participate in multiple upcoming institutional investor conferences. Details on the Company's participation appear below: Chardan Capital's Trending Issues in Drug Development Conference – April 29, 2025 (Virtual) David Hochman, Orchestra BioMed's Chairman and Chief Executive Officer, will participate in a fireside chat with Keay Nakae, Senior Research Analyst, Chardan on the topic of "Data & Reg

      4/28/25 4:30:00 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care

    $OBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Rtw Investments, Lp bought $149,201 worth of shares (49,900 units at $2.99) (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      5/1/25 8:18:11 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Rtw Investments, Lp bought $126,500 worth of shares (50,000 units at $2.53) (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      4/29/25 5:16:34 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Officer Hochman David P bought $18,640 worth of shares (4,000 units at $4.66), increasing direct ownership by 0.70% to 579,498 units (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      12/26/24 5:46:42 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care

    $OBIO
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Orchestra BioMed Holdings Inc.

      SCHEDULE 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

      5/1/25 5:41:46 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFA14A filed by Orchestra BioMed Holdings Inc.

      DEFA14A - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

      4/30/25 4:18:34 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEF 14A filed by Orchestra BioMed Holdings Inc.

      DEF 14A - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

      4/30/25 4:16:42 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care

    $OBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Orchestra BioMed Holdings Inc.

      SC 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

      8/7/24 5:19:57 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Orchestra BioMed Holdings Inc.

      SC 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

      8/7/24 5:16:55 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Orchestra BioMed Holdings Inc.

      SC 13G/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

      7/17/24 4:32:50 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care

    $OBIO
    Financials

    Live finance-specific insights

    See more
    • Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

      Hypertension is the most common comorbidity in the pacemaker population, affecting over 70% of patients or approximately 750,000 people annually worldwideMedtronic plc and Orchestra BioMed have an exclusive strategic collaboration for global development and commercialization of BackBeat Cardiac Neuromodulation Therapy™ (CNT), now also known as Atrioventricular Interval Modulation ("AVIM") therapy, for hypertensive pacemaker patientsBACKBEAT global pivotal study is expected to start before the end of 2023 IDE supported by data from the MODERATO II randomized pilot study that showed AVIM therapy drove significant and sustained reductions in blood pressure in hypertensive pacemaker patients Orc

      9/19/23 7:30:00 AM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products

    $OBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

      NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

      3/31/25 4:21:30 PM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products
    • Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

      The BACKBEAT global pivotal study is currently enrolling patients to evaluate the efficacy and safety of atrioventricular interval modulation ("AVIM") therapy for patients who have uncontrolled hypertension and a pacemaker indicationA globally recognized thought leader and innovator in cardiovascular technologies, including electrophysiology and cardiac rhythm management, Dr. Reddy currently serves as the Director of Cardiac Arrhythmia Services at The Mount Sinai Fuster Heart Hospital, the Director of Electrophysiology for the Mount Sinai Health System, and the Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at the Icahn School of Medicine a

      2/18/25 8:00:00 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

      Medical device industry veteran brings over three decades of expertise in M&A, as well as structured research and development ("R&D") collaborations aligned with Orchestra BioMed's partnership-enabled business model Mr. Cleary previously served as Senior Vice President ("SVP") of Corporate Development at Medtronic plc (NYSE:MDT) ("Medtronic"), where he played a key role in establishing the strategic collaboration between Orchestra BioMed and Medtronic for atrioventricular interval modulation ("AVIM") therapy in hypertension with increased cardiovascular riskEric A. Rose, M.D. to transition from Board Member to Board Member Emeritus and Strategic Advisor, continuing to provide invaluable expe

      2/5/25 8:00:00 AM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products